Skip to content
Companies

Petragen

Small molecules for abnormal mineralization diseases

Raised to date

$495K

of $1M offered across 1 Form D filing

Still open
$505K
Investors
9
Last filed
Jun 23, 2026

About

Petragen is a Yale-founded precision therapeutics company in Davie, Florida developing small-molecule treatments for diseases of abnormal mineralization. Its approach intervenes at the physical site where pathological mineralization occurs rather than at a distant signaling target. Named programs span periodontal disease, hypophosphatasia, and calcium pyrophosphate deposition disease. The company was co-founded by Yale pathologist Demetrios Braddock, MD, PhD, who serves as chief scientific officer, with David Kolb as CEO and president.

Targets the physical chemistry of pathological mineralization directly, and pursues orally available small molecules as alternatives to enzyme-replacement biologics that can cost up to $2 million per year and require near-daily injections.

Funding

  • EquityFiled Jun 23, 2026Form D
    $495K/ $1M

Product

Mineralization-targeted small molecule platform

Preclinical therapeutics

A preclinical therapeutic platform of small molecules that act at the point where abnormal mineralization occurs, applied across several bone, joint, and dental indications.

  • Small-molecule chemistry rather than injected biologics
  • Acts on the direct pathophysiology of mineralization instead of upstream signaling pathways
  • Applied across common and rare mineralization disorders

Built for

Patients with mineralization-related bone, joint, and dental disorders, reached through clinicians and payers; pharmaceutical partners for development and commercialization

People on file